21 May 2020: We added a link from recommendation 3.2 to the advice in NICE's COVID-19 rapid guideline: children and young people who are immunocompromised on factors to take into account when considering temporarily stopping some drugs. We aligned recommendation 1.4 with current government advice on social distancing.
30 April 2020: We added information to recommendation 3.2 to highlight that the half-life of some drugs means that immunosuppression will continue for some time after stopping treatment.
24 April 2020: We amended recommendation 4.9 to include switching from an intravenous treatment to a subcutaneous form of the same treatment. Subcutaneous infliximab is now available, so we deleted a recommendation on switching from infliximab to a different treatment in subcutaneous form. We also updated the table number in recommendation 6.1 in line with the updated NHS England guide on the management of rheumatology patients.